Contraindicated in patients with myasthenia gravis. Fatal or life-threatening acute respiratory failure reported. (See Myasthenia Gravis Patients under Cautions.)
REMS:
FDA approved a REMS for telithromycin to ensure that the benefits of a drug outweigh the risks. However, FDA later rescinded REMS requirements. See the FDA REMS page ([Web]) or the ASHP REMS Resource Center ([Web]).
Sign up with Facebook
